Nat. Rev. Nephrol. doi: /nrneph

Slides:

Advertisements

Similar presentations

Figure 1 Schematic representation of idiopathic nephrotic syndrome,

Advertisements

Volume 81, Issue 2, Pages (January 2012)

Figure 1 Disruption of phosphate homeostasis in chronic kidney disease (CKD) Figure 1 | Disruption of phosphate homeostasis in chronic kidney disease (CKD).

Volume 70, Issue 10, Pages (November 2006)

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 4 Interplay between acute kidney injury (AKI),

Figure 3 LncRNAs in kidney disease

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 2 Pathology of scleroderma renal crisis

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Interactions between adipose, the microbiome and kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 2 Physiological changes in the renal system in pregnancy

Figure 1 Types of coronary artery calcification

Figure 2 Proinflammatory mechanisms in CKD

Figure 1 The epigenetic landscape mediates the interplay between stressors and renal dysfunction Figure 1 | The epigenetic landscape mediates the interplay.

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 The fat–intestine–kidney axis

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Pathologic features of obesity-related glomerulopathy (ORG)

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 4 Tissular changes in crystalline CKD

Figure 7 The efficacy of phosphate-binder therapy

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Figure 5 Risk factor control in the intensive treatment group

Figure 2 The network of chronic diseases and their mutual influences

Figure 2 Three distinct mechanisms of activation of

Figure 1 The burden of chronic kidney disease (CKD)

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 2 Glomerular pathology in mice and humans with diabetic nephropathy Figure 2 | Glomerular pathology in mice and humans with diabetic nephropathy.

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Podocyte dysfunction is a common feature of renal injury

Figure 1 Sequential impact of diabetes platforms, genetic backgrounds and accelerators on albuminuria and kidney pathology in mouse models of diabetic.

Figure 1 Acute kidney injury and chronic kidney disease

Figure 4 The gut–kidney axis, inflammation and cardiovascular disease in CKD Figure 4 | The gut–kidney axis, inflammation and cardiovascular disease in.

Figure 2 The continuum of acute kidney injury (AKI),

Figure 4 Model of changes in the serum levels

Figure 2 Roles of mTOR complexes in the kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 Potential roles of phosphate and fibroblast growth factor 23 (FGF-23) in the development of cardiovascular disease in patients with chronic kidney.

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 The potential effects of nicotinamide adenine

Figure 6 Schematic of an analysis of a new biopsy

Nat. Rev. Nephrol. doi: /nrneph

Volume 80, Issue 10, Pages (November 2011)

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Volume 94, Issue 5, Pages (November 2018)

Figure 3 Loss of the glycocalyx leads to podocyte and kidney injury

Figure 3 Hypothetical trajectories of acute kidney disease (AKD)

Figure 5 The nephron-centric model of renal transplant fibrosis based on the injury-related molecular events observed in biopsy samples in the first year.

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 Hypothetical effect of starting therapy for autosomal

Nat. Rev. Nephrol. doi: /nrneph

Figure 4 Senotherapeutic targeting strategies

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Main triggers of senescence

Figure 3 Pathophysiological events and preventive

Figure 3 Preventive strategies for CSA-AKI

Figure 4 The relationship between the time-dependent changes in the expression of immunoglobulin, mast cell, acute kidney injury (AKI), and fibrillar collagen.

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Attributed cause of end-stage renal disease (ESRD) among 251 patients with SLE in the Georgia Lupus Registry who progressed to ESRD (1979–2012), overall.

Relationship between time from diagnosis of type 2 diabetes to renal biopsy and the proportion of biopsies with any diabetic nephropathy (DN) and any non-diabetic.

Epidemiologic data of primary glomerular diseases in western France

Presentation transcript:

Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.183 Figure 3 Senescent cell accumulation in the kidney associated with ageing, disease, and therapy Figure 3 | Senescent cell accumulation in the kidney associated with ageing, disease, and therapy. Senescent cells have been identified in a variety of locations within the nephron in association with renal ageing (part a), disease (part b), and therapy-induced damage (part c). a | Senescent cells are present in aged kidneys and are associated with glomerulosclerosis, interstitial fibrosis, and nephron atrophy. b | p16INK4a-positive or senescent cells are also present in kidneys in association with several renal diseases including chronic kidney disease (CKD), membraneous nephropathy (MN), focal segmental glomerular sclerosis (FSGS), minimal change disease (MCD); IgA nephropathy (IgAN), diabetic nephropathy, nephronophthisis (NPHP), and acute kidney injury (AKI). c | Senescent cells are also induced by transplant-associated stress. SASP, senescence-associated secretory phenotype. Sturmlechner, I. et al. (2016) Cellular senescence in renal ageing and disease Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.183